Epidemiology and Clinical Outcomes of Chronic Liver Disease

Chronic liver disease (CLD) affects millions worldwide and represents a leading cause of morbidity and mortality. The global burden is driven by viral hepatitis in high‐endemic regions, non‐alcoholic fatty liver disease (NAFLD) in populations with rising obesity and metabolic syndrome, and alcohol‐related liver disease (ALD) where harmful drinking persists. Incidence and mortality from cirrhosis continue to rise, reflected in increasing hospital admissions, escalating health‐care costs and greater demand for liver transplantation. Clinical outcomes range from asymptomatic fibrosis to decompensated cirrhosis—with complications such as ascites, variceal bleeding and hepatic encephalopathy—and hepatocellular carcinoma, which frequently arises in cirrhotic livers. Prognostic tools, including the Model for End‐stage Liver Disease (MELD), guide prioritisation for transplantation and forecast survival. Preventive measures—hepatitis B vaccination, antiviral therapies, lifestyle modifications and alcohol‐control policies—have demonstrated potential to alter disease trajectories, yet the expanding prevalence of metabolic risk factors underscores the need for sustained surveillance, early detection and targeted interventions.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Epidemiology and Clinical Outcomes of Chronic Liver Disease publication trend

The graph below shows the total number of articles in epidemiology and clinical outcomes of chronic liver disease across all publications each year (not limited to Nature Index journals).

Technical terms

Cirrhosis: Late stage of chronic liver disease marked by fibrosis and regenerative nodules impairing liver function.

Decompensated cirrhosis: Cirrhosis complicated by clinical events such as ascites, variceal bleeding or hepatic encephalopathy.

Hepatocellular carcinoma: Primary malignancy of the liver, often arising in the setting of chronic liver injury and cirrhosis.

Non‐alcoholic fatty liver disease (NAFLD): Spectrum of liver conditions characterised by steatosis in hepatocytes unrelated to significant alcohol intake.

Model for End‐stage Liver Disease (MELD): Scoring system based on laboratory values that predicts short‐term mortality to prioritise liver transplantation.

References

1. Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study. BMC Medicine (2023).
2. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLOS Medicine (2020).
3. Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults. JAMA Network Open (2020).